Biohaven is a innovative pharmaceutical company dedicated to discovering and developing new therapies for neurological and neuropsychiatric diseases, including rare disorders. Guided by science and driven to improve the lives of those with unmet medical needs, Biohaven challenges the status quo in the industry. Leveraging their proprietary platforms, Biohaven is advancing groundbreaking treatment options for debilitating diseases, including neurological and neuropsychiatric conditions.

They have achieved significant progress with various compounds, focusing on areas such as obsessive-compulsive disorder, spinocerebellar ataxia, and spinal muscular atrophy. With a commitment to following science, Biohaven combines internal research and development with intellectual property licensed from prestigious companies and institutions. Beyond neuroscience, they are expanding their focus to include chronic pain, cancer, and infectious diseases.

Embracing digital transformation, Biohaven harnesses the power of technology to enhance engagement and ensure the success of their novel treatments. With a mission to revolutionize the industry, Biohaven is just getting started